Indivior PLC (NASDAQ:INDV) Shares Sold by HighVista Strategies LLC

HighVista Strategies LLC lowered its stake in shares of Indivior PLC (NASDAQ:INDV) by 20.2% during the third quarter, Holdings Channel reports. The firm owned 142,634 shares of the company’s stock after selling 36,202 shares during the period. HighVista Strategies LLC’s holdings in Indivior were worth $1,405,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in INDV. Bank of New York Mellon Corp acquired a new stake in Indivior during the second quarter worth approximately $188,000. VELA Investment Management LLC acquired a new stake in Indivior during the second quarter worth approximately $235,000. XTX Topco Ltd acquired a new stake in Indivior during the second quarter worth approximately $249,000. Verition Fund Management LLC acquired a new stake in Indivior during the third quarter worth approximately $375,000. Finally, Cubist Systematic Strategies LLC raised its holdings in Indivior by 32.0% during the second quarter. Cubist Systematic Strategies LLC now owns 25,236 shares of the company’s stock worth $407,000 after purchasing an additional 6,121 shares in the last quarter. Institutional investors and hedge funds own 60.33% of the company’s stock.

Indivior Stock Up 0.2 %

Shares of Indivior stock opened at $11.23 on Tuesday. The firm’s fifty day simple moving average is $9.67 and its 200-day simple moving average is $12.24. Indivior PLC has a 12 month low of $7.33 and a 12 month high of $23.22. The company has a quick ratio of 0.65, a current ratio of 0.83 and a debt-to-equity ratio of 23.50.

Indivior (NASDAQ:INDV) last announced its earnings results on Thursday, October 24th. The company reported $0.54 EPS for the quarter, beating analysts’ consensus estimates of $0.39 by $0.15. Indivior had a negative net margin of 0.17% and a negative return on equity of 351.08%. The business had revenue of $307.00 million for the quarter, compared to analysts’ expectations of $302.25 million. As a group, analysts anticipate that Indivior PLC will post 1.66 earnings per share for the current year.

Analyst Ratings Changes

A number of equities analysts have recently commented on INDV shares. Craig Hallum cut their target price on shares of Indivior from $20.00 to $16.00 and set a “buy” rating on the stock in a report on Friday, October 11th. Piper Sandler reaffirmed an “overweight” rating and issued a $16.00 target price (up from $15.00) on shares of Indivior in a report on Friday, October 25th.

Indivior Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.